Effect Of Precooling On Physical Performance In Multiple Sclerosis
White AT, Wilson TE, Davis SL, Petajan JH
Mult Scler 2000 Jun;6(3):176-80
Univ of Utah, Dept of Exercise and Sport Science, Salt Lake City, Utah UT 84112, USA
PMID# 10871829; UI# 20332496
Many individuals with MS experience Heat Sensitivity that may be associated with transient increases in the frequency of clinical signs and symptoms.
Although physical activity may be beneficial for those with MS, induced thermal loads may preclude participation in exercise and other daily activities.
This project was designed to evaluate the effects of precooling on physical function. Six thermosensitive MS patients were studied.
Participants performed a graded exercise test to determine maximal Oxygen uptake (VO2max) on a combined arm-leg ergometer.
Thermal load was induced by 30 min of exercise under noncooled and precooled conditions at a workrate corresponding to 60% VO2max.
Precooling consisted of 30 min lower body immersion in 16 - 17 degrees C water. Fatigue and 25-ft walk performance were assessed before, immediately after, and 30 min following exercise.
No treatment differences in VO2 were observed.
Rectal temperature, heart rate, and rating of perceived exertion (RPE) were significantly lower during the precooled exercise trial compared to the noncooled trial.
Immediately following exercise, 25-ft walk performance and Fatigue scores showed significantly greater deterioration in the noncooled condition.
Precooling was effective in preventing gains in core temperature with physical work and may allow Heat-Sensitive individuals with MS to exercise with greater physical comfort.
Multiple Sclerosis (2000) 6, 176 - 180
Activated T-Cell Changes In Blood Correlate With Disease Activity In Multiple Sclerosis
Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL
Arch Neurol 2000 Aug;57(8):1183-1189
Center for Neurologic Diseases, 77 Ave Louis Pasteur, Boston, MA 02115
To determine whether changes in activation markers on peripheral blood T-Cells correlate with disease activity in patients with Multiple Sclerosis.
In a prospective longitudinal study during 1 year, we analyzed the change in percentage of activated T-Lymphocytes in the peripheral blood of 40 patients with Multiple Sclerosis in relation to clinical findings and changes on Brain Magnetic Resonance Imaging (MRI) scans.
The patients underwent repeated imaging of the Brain (mean number of MRIs for each patient, 22) at the time blood samples were obtained as well as at monthly Neurological Examinations, and at the time of scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and Ambulation Index Scale.
A change in the percentage of cells expressing the activation markers InterLeukin 2 receptor (CD25+), Class II Major Histocompatibility Complex (MHC) (I3) or surface Dipeptidyl Peptidase (CD26+) correlated significantly with a change in lesion volume or a change in number of Gadolinium-enhancing lesions as detected on MRI.
Changes in CD25+ cells and in CD4+ cells expressing class II MHC also correlated with changes in disability as measured by EDSS in patients with Relapsing/Remitting Disease, and changes in CD4+, CD25+ cells correlated with the occurrence of attacks in patients with Relapsing/Remitting Disease.
These correlations are dependent on measurement of changes between time points sampled at 1- or 2-week intervals.
There is a linkage between peripheral T-Lymphocyte activation as measured by cell surface markers and disease activity in patients with Multiple Sclerosis.
Arch Neurol 2000;57:1183-1189
Acute Aphasia In Multiple Sclerosis
Devere TR, Trotter JL, Cross AH
Arch Neurol 2000 Aug;57(8):1207-1209
Barnes Jewish Hospital, Campus Box 8111, 660 S Euclid Ave, St Louis, MO 63110
Acute Aphasia is rare in Multiple Sclerosis. We describe 3 patients with Multiple Sclerosis who had acute exacerbations presenting as Aphasias.
One patient had a mixed TransCortical Aphasia, 1 had a TransCortical motor Aphasia, and 1 had a Broca Aphasia. Magnetic Resonance Imaging scans of the Brain with contrast enhancement revealed new White Matter lesions in the Left Hemisphere in all 3 patients.
Two of the 3 patients had a good response to treatment with MethylPrednisolone Sodium Succinate.
Arch Neurol 2000;57:1207-1209
Monocytes In Multiple Sclerosis: Phenotype And Cytokine Profile
Kouwenhoven M, Teleshova N, Ozenci V, Press R, Link H
J NeuroImmunol 2001 Jan 1;112(1-2):197-205
Karolinska Institutet, Huddinge Univ Hospital, NeuroImmunology Unit, Division of Neurology, Stockholm, Sweden
Multiple Sclerosis (MS) is an inflammatory DeMyelinating disease characterized by Immune abnormalities in the Central Nervous System (CNS) as well as systemically.
Activated, blood-borne Monocytes are abundant in MS lesions, the properties of circulating Monocytes are incompletely known.
To delineate phenotype and levels of Cytokine secreting Monocytes in MS patients' blood, ELISPOT assays were used for detection and enumeration of Monocytes secreting the Cytokines IL-6, IL-12, TNF- and IL-10.
In parallel, the expression by Monocytes of co-stimulatory molecules (CD40, CD80, CD86), Major Histocompatibility Complex molecules (HLA-ABC, HLA-DR) and Fcreceptors (CD16, CD64) was examined by flow cytometry.
Levels of blood Monocytes secreting IL-6 and IL-12 were higher in patients with untreated MS and Other Neurological Diseases (OND) compared to healthy controls, while levels of Monocytes secreting TNF- and IL-10 did not differ between groups.
MS patients' blood Monocytes also displayed elevated mean fluorescence intensity for the co-stimulatory molecule CD86, and MS patients with longer disease duration (>10 years) and higher disease severity (EDSS >3) had higher percentages of CD80 expressing Monocytes compared to patients with short duration or lower severity.
In conclusion, Monocyte aberrations occur in MS and may change over the disease course.
Extended Observations On The Association Of HHV-6 And Multiple Sclerosis
Berti R, Soldan SS, Akhyani N, McFarland HF, Jacobson S
J NeuroVirol 2000 May;6 Suppl 2:S85-7
National Institutes of Health, NeuroImmunology Branch, Viral Immunology Section, Bethesda, Maryland, MD 20892, USA
PMID# 10871792; UI# 20332469
Throughout the years, a long list of Viruses has been associated with Multiple Sclerosis (MS), however no virus to date has been definitively identified as the etiologic agent of this disease.
Recently, Human HerpesVirus 6 (HHV-6), a newly described HerpesVirus, has been suggested to play a role in MS based on: ImmunoHistoChemical demonstration of HHV-6 in MS plaques.
Increased AntiBodies response to HHV-6 in Sera and CSF of MS patients, and the demonstration of HHV-6 DNA in the Serum of MS patients but not in normal individuals. To extend these observations we have focused our research in multiple directions.
We have increased the number of MS patients tested for HHV-6 Serum DNA providing confirmation of our previous study. Additionally we have investigated a possible correlation between HHV-6 Viremia and clinical activity.
Finally to provide insight into the PathoGenesis of this disease, we have begun to characterize the Cellular Immune Response of MS patients to HHV-6. Collectively these studies will help to define the role that HHV-6 may play in the PathoGenesis of MS.